Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Covington
Harvard Business School
Julphar
Medtronic
McKinsey
Deloitte
Baxter
Cipla

Generated: November 14, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022370

« Back to Dashboard

NDA 022370 describes CONZIP, which is a drug marketed by Cipher Pharms Inc and is included in one NDA. It is available from fifteen suppliers. There is one patent protecting this drug. Additional details are available on the CONZIP profile page.

The generic ingredient in CONZIP is tramadol hydrochloride. There are thirty-six drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the tramadol hydrochloride profile page.
Summary for 022370
Tradename:CONZIP
Applicant:Cipher Pharms Inc
Ingredient:tramadol hydrochloride
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 022370
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for 022370
Suppliers and Packaging for NDA: 022370
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CONZIP tramadol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022370 NDA AUTHORIZED GENERIC Trigen Laboratories, LLC 13811-689 13811-689-30 30 CAPSULE in 1 BOTTLE, PLASTIC (13811-689-30)
CONZIP tramadol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022370 NDA AUTHORIZED GENERIC Trigen Laboratories, LLC 13811-690 13811-690-30 30 CAPSULE in 1 BOTTLE, PLASTIC (13811-690-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength100MG
Approval Date:May 7, 2010TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Apr 11, 2022Product Flag?YSubstance Flag?Delist Request?
Patented Use:USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength200MG
Approval Date:May 7, 2010TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Apr 11, 2022Product Flag?YSubstance Flag?Delist Request?
Patented Use:USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength300MG
Approval Date:May 7, 2010TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Apr 11, 2022Product Flag?YSubstance Flag?Delist Request?
Patented Use:USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Moodys
Cantor Fitzgerald
Mallinckrodt
UBS
Boehringer Ingelheim
Deloitte
QuintilesIMS
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.